Organon Pharmaceuticals USA (Roseland, NJ) recently announced the availability of Follistim AQ in 75-internationalunit (IU) and 150-IU presentations in single-use 0.5-mL vials in premixed solutions, thus eliminating reconstitution. Follistim AQ is indicated for the development of multiple follicles in ovulatory patients participating in an assisted reproductive technology (ART) program. The product also is indicated for the induction of ovulation and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. The additional presentations complement Organon's existing fertility product portfolio of the Follistim AQ Cartridge in 300-, 600-, and 900-IU strengths, which are designed to be used with the Follistim Pen. For patients participating in the ART program, a starting dose of 150 to 225 IU of Follistim AQ is recommended for at least the first 4 days of treatment. The recommended starting dose of Follistim AQ for ovulation induction is 75 IU for up to 14 days. For more information, visit www.follistim.com, or call 800-241-8812.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs